Aurinia Pharmaceuticals Stock Price on November 5, 2024
| AUPH Stock | USD 8.86 0.01 0.11% |
Below is the normalized historical share price chart for Aurinia Pharmaceuticals extending back to July 16, 2001. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Aurinia Pharmaceuticals stands at 8.86, as last reported on the 1st of December, with the highest price reaching 9.02 and the lowest price hitting 8.77 during the day.
If you're considering investing in Aurinia Stock, it is important to understand the factors that can impact its price. Aurinia Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. Aurinia Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18% return per unit of risk over the last 3 months. We have found thirty technical indicators for Aurinia Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Aurinia Pharmaceuticals' Mean Deviation of 1.92, risk adjusted performance of 0.1449, and Downside Deviation of 2.11 to double-check if our risk estimates are consistent with your expectations.
As of now, Aurinia Pharmaceuticals' Common Stock Total Equity is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Common Stock is estimated to increase to about 1.3 B, while Other Stockholder Equity is projected to decrease to under 66.4 M. . As of now, Aurinia Pharmaceuticals' Price Fair Value is increasing as compared to previous years. Aurinia Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 26th of January 1999 | 200 Day MA 6.1021 | 50 Day MA 7.5652 | Beta 1.456 |
Aurinia |
Sharpe Ratio = 0.181
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AUPH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Aurinia Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aurinia Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 3.2695 | Enterprise Value Ebitda 229.5381 | Price Sales 5.7568 | Shares Float 128.9 M | Wall Street Target Price 10.8357 |
Related Headline
TG Therapeutics Headline on 5th of November 2024
Earnings call TG Therapeutics reports robust growth for BRIU... by investing.com
Earnings call TG Therapeutics reports robust growth for BRIUMVI
Aurinia Pharmaceuticals Valuation on November 5, 2024
It is possible to determine the worth of Aurinia Pharmaceuticals on a given historical date. On November 5, 2024 Aurinia was worth 7.17 at the beginning of the trading date compared to the closed value of 7.32. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Aurinia Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Aurinia Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aurinia Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Aurinia Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 7.28 | 7.28 | 7.03 | 7.21 | 1,196,667 | |
11/05/2024 | 7.17 | 7.35 | 7.10 | 7.32 | 948,538 |
| 7.45 | 7.56 | 7.33 | 7.52 | 1,596,101 |
| Backtest Aurinia Pharmaceuticals | | | Aurinia Pharmaceuticals History | | | Aurinia Pharmaceuticals Valuation | Previous | Next |
Aurinia Pharmaceuticals Trading Date Momentum on November 5, 2024
| On November 06 2024 Aurinia Pharmaceuticals was traded for 7.52 at the closing time. The top price for the day was 7.56 and the lowest listed price was 7.33 . The trading volume for the day was 1.6 M. The trading history from November 6, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 2.73% . The overall trading delta against the current closing price is 14.21% . |
Aurinia Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Aurinia Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Aurinia financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Aurinia Pharmaceuticals Stock history
Aurinia Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Aurinia is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Aurinia Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Aurinia Pharmaceuticals stock prices may prove useful in developing a viable investing in Aurinia Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 143.2 M | 150.4 M | |
| Net Loss | -97.4 M | -92.5 M |
Aurinia Pharmaceuticals Quarterly Net Working Capital |
|
Aurinia Pharmaceuticals Stock Technical Analysis
Aurinia Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Aurinia Pharmaceuticals Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Aurinia Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Aurinia Pharmaceuticals December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Aurinia Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aurinia Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Aurinia Pharmaceuticals stock market strength indicators, traders can identify Aurinia Pharmaceuticals entry and exit signals to maximize returns
Aurinia Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Aurinia Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Aurinia Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Aurinia to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1449 | |||
| Jensen Alpha | 0.3795 | |||
| Total Risk Alpha | 0.0254 | |||
| Sortino Ratio | 0.1614 | |||
| Treynor Ratio | 0.6693 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |